Gemtuzumab Ozogamicin (anti-CD33 ADC for AML) and Inotuzumab Ozogamicin (anti-CD22 ADC for ALL): Gentuzumab Ozogamicin carry a calicheamicin payload. The gene discussed is CD22; the disease is acute myeloid leukemia.